Breast carcinoma chemoprevention in the community setting: Estimating risks and benefits

Abenaa M. Brewster, Dana Christo, Hong Chen Lai, Kathy Helzlsouer

Research output: Contribution to journalArticle

Abstract

BACKGROUND. The United States Preventive Services Task Force recommends that women who are at both high risk for breast carcinoma and low risk for adverse events should receive counseling regarding tamoxifen for chemoprevention. Estimates of the risks and benefits of tamoxifen based on results from clinical trials may not reflect the real-world experience. The authors determined the prevalence of women in a community-based cohort who would meet the definition of high risk for breast carcinoma and calculated the number of women needed to screen to determine one for whom the benefits of tamoxifen would outweigh the risks. Baseline incidence also was examined for adverse health events in this community-based cohort compared with participants in the Breast Cancer Prevention Trial. METHODS. The study participants were women ages 40-70 years (n = 6048 women) who were members of the CLUE II cohort, which started in 1989, and who responded to questionnaire surveys in 1996 and 2000. RESULTS. Eighteen percent of all women had a 5-year risk of invasive breast carcinoma ≥ 1.66%. The number of women needed to screen to find 1 woman for whom the benefits outweighed the risks of tamoxifen ranged from 26 women ages 40-49 years to 142 women ages 60-70 years. For women who had undergone a hysterectomy, the numbers needed to screen were lower. Baseline incidence rates of fracture and thromboembolic disease were higher in the community-based cohort compared with the rates observed among prevention trial participants; thus, fewer women had to be treated with tamoxifen to prevent one fracture. However, fewer women in the community also had to be treated to observe harm with a thromboembolic event. CONCLUSIONS. Clinicians who counsel women about tamoxifen should take into consideration community-level risks and benefits.

Original languageEnglish (US)
Pages (from-to)1147-1153
Number of pages7
JournalCancer
Volume103
Issue number6
DOIs
StatePublished - Mar 15 2005

Fingerprint

Chemoprevention
Breast Neoplasms
Tamoxifen
Incidence
Advisory Committees
Hysterectomy
Counseling

Keywords

  • Breast carcinoma
  • Chemoprevention
  • Community-based cohort
  • Risk/benefit
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Breast carcinoma chemoprevention in the community setting : Estimating risks and benefits. / Brewster, Abenaa M.; Christo, Dana; Lai, Hong Chen; Helzlsouer, Kathy.

In: Cancer, Vol. 103, No. 6, 15.03.2005, p. 1147-1153.

Research output: Contribution to journalArticle

Brewster, Abenaa M. ; Christo, Dana ; Lai, Hong Chen ; Helzlsouer, Kathy. / Breast carcinoma chemoprevention in the community setting : Estimating risks and benefits. In: Cancer. 2005 ; Vol. 103, No. 6. pp. 1147-1153.
@article{e2db75ae712f4f1482bdecd15aac64a2,
title = "Breast carcinoma chemoprevention in the community setting: Estimating risks and benefits",
abstract = "BACKGROUND. The United States Preventive Services Task Force recommends that women who are at both high risk for breast carcinoma and low risk for adverse events should receive counseling regarding tamoxifen for chemoprevention. Estimates of the risks and benefits of tamoxifen based on results from clinical trials may not reflect the real-world experience. The authors determined the prevalence of women in a community-based cohort who would meet the definition of high risk for breast carcinoma and calculated the number of women needed to screen to determine one for whom the benefits of tamoxifen would outweigh the risks. Baseline incidence also was examined for adverse health events in this community-based cohort compared with participants in the Breast Cancer Prevention Trial. METHODS. The study participants were women ages 40-70 years (n = 6048 women) who were members of the CLUE II cohort, which started in 1989, and who responded to questionnaire surveys in 1996 and 2000. RESULTS. Eighteen percent of all women had a 5-year risk of invasive breast carcinoma ≥ 1.66{\%}. The number of women needed to screen to find 1 woman for whom the benefits outweighed the risks of tamoxifen ranged from 26 women ages 40-49 years to 142 women ages 60-70 years. For women who had undergone a hysterectomy, the numbers needed to screen were lower. Baseline incidence rates of fracture and thromboembolic disease were higher in the community-based cohort compared with the rates observed among prevention trial participants; thus, fewer women had to be treated with tamoxifen to prevent one fracture. However, fewer women in the community also had to be treated to observe harm with a thromboembolic event. CONCLUSIONS. Clinicians who counsel women about tamoxifen should take into consideration community-level risks and benefits.",
keywords = "Breast carcinoma, Chemoprevention, Community-based cohort, Risk/benefit, Tamoxifen",
author = "Brewster, {Abenaa M.} and Dana Christo and Lai, {Hong Chen} and Kathy Helzlsouer",
year = "2005",
month = "3",
day = "15",
doi = "10.1002/cncr.20882",
language = "English (US)",
volume = "103",
pages = "1147--1153",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Breast carcinoma chemoprevention in the community setting

T2 - Estimating risks and benefits

AU - Brewster, Abenaa M.

AU - Christo, Dana

AU - Lai, Hong Chen

AU - Helzlsouer, Kathy

PY - 2005/3/15

Y1 - 2005/3/15

N2 - BACKGROUND. The United States Preventive Services Task Force recommends that women who are at both high risk for breast carcinoma and low risk for adverse events should receive counseling regarding tamoxifen for chemoprevention. Estimates of the risks and benefits of tamoxifen based on results from clinical trials may not reflect the real-world experience. The authors determined the prevalence of women in a community-based cohort who would meet the definition of high risk for breast carcinoma and calculated the number of women needed to screen to determine one for whom the benefits of tamoxifen would outweigh the risks. Baseline incidence also was examined for adverse health events in this community-based cohort compared with participants in the Breast Cancer Prevention Trial. METHODS. The study participants were women ages 40-70 years (n = 6048 women) who were members of the CLUE II cohort, which started in 1989, and who responded to questionnaire surveys in 1996 and 2000. RESULTS. Eighteen percent of all women had a 5-year risk of invasive breast carcinoma ≥ 1.66%. The number of women needed to screen to find 1 woman for whom the benefits outweighed the risks of tamoxifen ranged from 26 women ages 40-49 years to 142 women ages 60-70 years. For women who had undergone a hysterectomy, the numbers needed to screen were lower. Baseline incidence rates of fracture and thromboembolic disease were higher in the community-based cohort compared with the rates observed among prevention trial participants; thus, fewer women had to be treated with tamoxifen to prevent one fracture. However, fewer women in the community also had to be treated to observe harm with a thromboembolic event. CONCLUSIONS. Clinicians who counsel women about tamoxifen should take into consideration community-level risks and benefits.

AB - BACKGROUND. The United States Preventive Services Task Force recommends that women who are at both high risk for breast carcinoma and low risk for adverse events should receive counseling regarding tamoxifen for chemoprevention. Estimates of the risks and benefits of tamoxifen based on results from clinical trials may not reflect the real-world experience. The authors determined the prevalence of women in a community-based cohort who would meet the definition of high risk for breast carcinoma and calculated the number of women needed to screen to determine one for whom the benefits of tamoxifen would outweigh the risks. Baseline incidence also was examined for adverse health events in this community-based cohort compared with participants in the Breast Cancer Prevention Trial. METHODS. The study participants were women ages 40-70 years (n = 6048 women) who were members of the CLUE II cohort, which started in 1989, and who responded to questionnaire surveys in 1996 and 2000. RESULTS. Eighteen percent of all women had a 5-year risk of invasive breast carcinoma ≥ 1.66%. The number of women needed to screen to find 1 woman for whom the benefits outweighed the risks of tamoxifen ranged from 26 women ages 40-49 years to 142 women ages 60-70 years. For women who had undergone a hysterectomy, the numbers needed to screen were lower. Baseline incidence rates of fracture and thromboembolic disease were higher in the community-based cohort compared with the rates observed among prevention trial participants; thus, fewer women had to be treated with tamoxifen to prevent one fracture. However, fewer women in the community also had to be treated to observe harm with a thromboembolic event. CONCLUSIONS. Clinicians who counsel women about tamoxifen should take into consideration community-level risks and benefits.

KW - Breast carcinoma

KW - Chemoprevention

KW - Community-based cohort

KW - Risk/benefit

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=14744275696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14744275696&partnerID=8YFLogxK

U2 - 10.1002/cncr.20882

DO - 10.1002/cncr.20882

M3 - Article

C2 - 15674856

AN - SCOPUS:14744275696

VL - 103

SP - 1147

EP - 1153

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -